Weekly paclitaxel in the treatment of metastatic and/or recurrent non-small cell lung cancer
- PMID: 12505597
- DOI: 10.1016/s1040-8428(02)00104-x
Weekly paclitaxel in the treatment of metastatic and/or recurrent non-small cell lung cancer
Abstract
Weekly paclitaxel was initially used to exploit the radiosensitizing properties of the drug. However, the observed improvement in therapeutic index with this regimen encouraged further use of weekly regimens, with and without radiotherapy, as a single-agent or in combination with other regimens. Single-agent weekly paclitaxel, at doses ranging from 50 to 200 mg/m(2)/week, has been associated with response rates of 23-56% with acceptable toxicity. Weekly paclitaxel has also been combined with carboplatin and vinorelbine in two-drug combinations and with cisplatin plus gemcitabine and cisplatin plus vinorelbine in three-drug regimens. Response rates with weekly paclitaxel in combination chemotherapy have ranged from 16 to 71%. Paclitaxel is particularly suited to combined modality therapy with radiation in non-small cell lung cancer, because of its modest toxicity profile, significant antineoplastic activity, ease of administration and potential for radiosensitization. Studies of weekly paclitaxel given together with radiotherapy, with or without carboplatin, have produced response rates of 71-86% with median survival durations of 17-20.5 months.
Similar articles
-
Docetaxel in combination with platinums (cisplatin or carboplatin) in advanced and metastatic non-small cell lung cancer.Semin Oncol. 2002 Jun;29(3 Suppl 12):4-9. doi: 10.1053/sonc.2002.34255. Semin Oncol. 2002. PMID: 12170445 Review.
-
Paclitaxel in lung cancer: 1-hour infusions given alone or in combination chemotherapy.Semin Oncol. 1995 Dec;22(6 Suppl 15):45-9. Semin Oncol. 1995. PMID: 8643970 Clinical Trial.
-
Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel.Cancer. 2002 Sep 15;95(6):1265-73. doi: 10.1002/cncr.10835. Cancer. 2002. PMID: 12216094 Clinical Trial.
-
The multifractionated, twice-weekly dose schedule for a three-drug chemotherapy regimen: a phase I-II study of paclitaxel, cisplatin, and vinorelbine.Cancer. 1999 Jan 15;85(2):499-503. doi: 10.1002/(sici)1097-0142(19990115)85:2<499::aid-cncr31>3.0.co;2-v. Cancer. 1999. PMID: 10023721 Clinical Trial.
-
Paclitaxel for non-small cell lung cancer.Expert Opin Pharmacother. 2004 Aug;5(8):1771-80. doi: 10.1517/14656566.5.8.1771. Expert Opin Pharmacother. 2004. PMID: 15264992 Review.
Cited by
-
Pharmacokinetic profile of paclitaxel in the plasma, lung, and diaphragm following intravenous or intrapleural administration in rats.Thorac Cancer. 2015 Jan;6(1):43-8. doi: 10.1111/1759-7714.12139. Epub 2015 Jan 7. Thorac Cancer. 2015. PMID: 26273334 Free PMC article.
-
Gemcitabine with either paclitaxel or vinorelbine vs paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients.Br J Cancer. 2004 Aug 2;91(3):489-97. doi: 10.1038/sj.bjc.6602011. Br J Cancer. 2004. PMID: 15266334 Free PMC article. Clinical Trial.
-
Strategy to enhance lung cancer treatment by five essential elements: inhalation delivery, nanotechnology, tumor-receptor targeting, chemo- and gene therapy.Theranostics. 2019 Oct 22;9(26):8362-8376. doi: 10.7150/thno.39816. eCollection 2019. Theranostics. 2019. PMID: 31754402 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical